# NIH Reporter #5R01AG063826-05

Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial

**Recipient:** Not Specified

**Award Amount:** $6,580,973.00
**Ceiling:** $6,580,973.00

**Awarded:** July 11, 2025

**Identifier:** 5R01AG063826-05

Phase 2 clinical trial funded by the National Institute on Aging to evaluate Allopregnanolone as a regenerative therapeutic for Alzheimer's disease, with a total award amount of approximately $6.58 million.

### Description

This project addresses the urgent need to develop therapeutics to delay and treat Alzheimer’s disease (AD). The Phase 2 clinical trial involves a regenerative treatment regimen of Allopregnanolone (Allo) administered over 18 months, including a placebo-controlled period and a delayed-start period. The primary outcome is the rate of change in ADAS-cog14 score after 12 months.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/10851927)